**Supplementary table 4:** Comparison of FCal between diagnosis, sex, age, smoking status and disease duration within a medication group

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Parameter** | **Lab marker** | **Medication** | **GMR (95% CI)** | **p-value** |
| Diagnosis (CD vs. UC) | FCal | InfliximabVedolizumab | 0.98 (0.51; 1.85)1.18 (0.20; 7.12) | 0.940.86 |
| Sex (male vs. female) | FCal | InfliximabVedolizumab | 0.83 (0.47; 1.47)3.12 (0.46; 21.36) | 0.520.26 |
| Age | FCal | InfliximabVedolizumab | 1.00 (0.98; 1.02)0.98 (0.93; 1.04) | 0.690.55 |
| Smoker (yes vs. no) | FCal | InfliximabVedolizumab | 1.70 (0.89; 3.24)0.34 (0.06; 1.95) | 0.110.24 |
| Smoker (ex vs. no) | FCal | InfliximabVedolizumab | 1.59 (0.70; 3.63)1.38 (0.11; 17.74) | 0.270.81 |
| Disease duration | FCal | InfliximabVedolizumab | 1.00 (0.97; 1.03)1.06 (0.94; 1.20) | 0.810.34 |